BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22286396)

  • 1. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
    Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
    Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.
    Fradet V; Lessard L; Bégin LR; Karakiewicz P; Masson AM; Saad F
    Clin Cancer Res; 2004 Dec; 10(24):8460-4. PubMed ID: 15623625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
    Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
    Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy.
    Barlow LJ; Badalato GM; Bashir T; Benson MC; McKiernan JM
    BJU Int; 2010 Jun; 105(12):1646-9. PubMed ID: 19863523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
    Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
    J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience.
    Audenet F; Comperat E; Seringe E; Drouin SJ; Richard F; Cussenot O; Bitker MO; Rouprêt M
    Urol Oncol; 2011; 29(6):602-7. PubMed ID: 19926312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of biochemical recurrence after radical prostatectomy using peritumoral lymphatic vessel density in biopsy specimens in patients with localized prostate cancer.
    Kuroda K; Horiguchi A; Asano T; Tasaki S; Yoshii H; Sato A; Asakuma J; Ito K; Seguchi K; Sumitomo M; Asano T
    Urol Int; 2012; 88(1):18-24. PubMed ID: 22222198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.